CareFusion to offer Pyxis products to US hospitals
CareFusion will provide the VA with a suite of positive patient identification products to help reduce the potential for errors during blood transfusion and specimen collection. The Pyxis
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
The single-arm pivotal trial assessed efficacy and safety of single-agent brentuximab vedotin in relapsed or refractory, post-autologous stem cell transplant (ASCT) Hodgkin lymphoma patients. Brentuximab vedotin is an